Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone
Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone
复制标题
DOI：
10.1016/j.ajo.2006.10.050
复制
发表时间：
2007-03-01
影响因子：
4.2
通讯作者：
Tano, Yasuo
中科院分区：
文献类型：
--
作者：
Gomi, Fumi;Nishida, Kentaro;Tano, Yasuo
目的：评价贝伐单抗玻璃体内注射治疗后路曲安奈德亚丁注射液难治性特发性脉络膜新生血管（CNV）的短期、短期疗效和安全性。设计：非比较性干预性病例系列。方法：对10例特发性CNV患者玻璃体内注射贝伐单抗，其中后路曲安奈德次注射无效超过3个月。主要结局指标是注射贝伐单抗前后最佳矫正视力（BCVA）、视网膜中央厚度（CRT）和荧光素血管造影结果的变化。结果：治疗后1个月BCVA改善（P = 0.029）持续至3个月（P = 0.003）。CRT明显降低（P < 0.001）。治疗3个月后，7只眼睛的特发性CNV渗漏停止，2只眼睛减少，1只眼睛继续。在一名患者中，结膜肿胀在注射后出现，但在再次注射后消退且未复发。无其他并发症发生。结论：玻璃体内注射贝伐单抗可改善特发性CNV对曲安奈德药物难治性眼部的BCVA。
PURPOSE: To assess short,term efficacy and safety of intravitreal bevacizumab injections for idiopathic choroidal neovascularization (CNV) refractory to posterior subtenon triamcinolone injections.DESIGN: Noncomparative, interventional case series.METHODS: Intravitreal bevacizumab was injected into 10 eyes with idiopathic CNV in which posterior subtenon triamcinolone injections were not efficacious for more than three months. The main outcome measures were changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and fluorescein angiography findings before and after bevacizumab injection.RESULTS: After treatment, the BCVA improvement at one month (P = .029) continued to three months (P = .003). CRT decreased significantly (P < .001). Leakage from idiopathic CNV three months after treatment stopped in seven eyes, decreased in two, and continued in one. In one patient, conjunctival swelling developed after the injection but resolved and did not recur after another injection. No other complications developed.CONCLUSIONS: Intravitreal bevacizumab improves BCVA in eyes with idiopathic CNV refractory to triamcinolone.